Skip to main content
. 2025 Jul 9;16:1548710. doi: 10.3389/fphar.2025.1548710

TABLE 3.

Baseline results.

Strategies and scenarios Total cost, $ LYs QALYs ICER per LY ICER per QALY
Sintilimab group 100,097.40 12.51 8.81 5,721.08 7,819.66
EFS state 71,396.07 8.84 6.72 - -
PD state 28,701.33 3.67 2.09 - -
Standard therapy group 75,888.80 8.27 5.71 - -
EFS state 40,446.13 5.24 3.98 - -
PD state 35,442.67 3.03 1.73 - -

Abbreviation: ICER, incremental cost-effectiveness ratio; LY, life-year; QALY, quality-adjusted life-year.